Table 3 The league table for OS estimates interventions according to their relative effects in first part network analysis

− 0.02 (− 0.41,0.37)

Atezolizumab (71.1%)

0.22 (−0.35,0.80)

0.24 (− 0.27,0.76)

Icrucumab+Taxane (36.3%)

0.47 (−0.05,0.99)

0.49 (0.03,0.95)^b

0.25 (−0.38,0.87)

Pazopanib (11.5%)

−0.14 (− 0.53,0.25)

−0.12 (− 0.38,0.14)

−0.36 (− 0.88,0.15)

− 0.61 (− 1.07,-0.15)

Pemborlizumab (87.5%)

− 0.09 (− 0.67,0.50)

−0.07 (− 0.60,0.46)

−0.31 (− 0.99,0.37)

−0.56 (− 1.19,0.08)

0.05 (− 0.48,0.58)

Ramucirumab+Taxane (74.6%)

0.22 (−0.10,0.55)

0.24 (0.03,0.46)

−0.00 (− 0.47,0.47)

−0.25 (− 0.66,0.16)

0.36 (0.15,0.57)

0.31 (− 0.18,0.80)

Taxane (31.6%)

0.41 (−0.11,0.93)

0.43 (−0.02,0.89)

0.19 (− 0.43,0.81)

−0.06 (− 0.63,0.52)

0.55 (0.10,1.01)

0.50 (− 0.13,1.13)

0.19 (− 0.21,0.59)

Vandetanib+Taxane (16.2%)

0.07 (− 0.34,0.48)

0.09 (− 0.11,0.30)

−0.15 (− 0.68,0.38)

−0.40 (− 0.88,0.08)

0.21 (− 0.04,0.46)

0.16 (− 0.39,0.71)

−0.15 (− 0.40,0.10)

−0.34 (− 0.82,0.13)

Vinflunine (54.6%)